UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the

~~the~~ Securities Exchange Act of 1934

Date of Report: June 11 20, 2012

(Date of earliest event reported)

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-31982

91-1689591

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

13400 NE 20^th Street, Suite 44

Bellevue, Washington 98005

(Address of principal executive offices and zip code)

(425) 368-1050

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SCOLR PHARMA, INC.

FORM 8-K

Item 12.0102. ~~Entry~~Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Conditions.

On June 1120, 2012, SCOLR Pharma, Inc. ~~(the~~announced ~~“Company”)~~its ~~closed~~unaudited ~~the~~net ~~second~~sales ~~and final tranche~~ of ~~the previously announced private placement of~~ its 8%nutritional ~~Senior~~products ~~Secured~~for ~~Convertible Debentures (~~the ~~“2012~~ ~~Debentures”).~~fourth ~~The~~quarter ~~Company~~and ~~raised~~year aended ~~total~~December ~~of $1~~31,~~350,000~~ in2011 and the ~~offering.~~first ~~The~~quarter ~~Company~~ended ~~intends~~March to31, 2012. A ~~use~~copy of the ~~net~~press ~~proceeds~~release ~~for~~containing ~~working~~this ~~capital~~information ~~and~~is ~~general~~attached ~~corporate~~to ~~purposes,~~this ~~primarily~~current inreport ~~support~~as ofExhibit ~~its nutritional products business~~99. 1.

The ~~purchase~~information contained ~~and~~herein, ~~sale~~including of the ~~2012~~exhibit ~~Debentures~~attached inhereto, ~~the~~is ~~offering~~being ~~was~~furnished ~~effected~~and ~~pursuant~~shall tonot abe ~~Securities~~deemed ~~Purchase~~“filed” ~~Agreement~~for ~~among~~purposes ~~the~~of ~~Company~~Section 18 ~~and the purchasers~~ of the ~~2012~~Securities ~~Debentures. To proceed with the offering~~ and ~~issuance~~Exchange Act of ~~the~~1934, ~~2012~~as ~~Debentures~~amended, ~~the~~or ~~Company~~otherwise ~~obtained~~subject ~~the~~to ~~requisite consent of~~ the ~~holders~~liabilities of that ~~its~~Section 8%or ~~Senior~~Sections ~~Secured~~11 ~~Convertible~~and ~~Debentures~~12(a)(2) ~~issued~~of ~~in June, 2011 (~~the ~~“2011 Debentures,”~~Securities ~~and~~Act ~~together~~of ~~with the 2012 Debentures~~1933, ~~the~~as ~~“Debentures”)~~amended. ~~Such~~The ~~consent~~information ~~was~~contained ~~given~~herein ~~pursuant to a Consent, Waiver~~ and ~~Forbearance~~in ~~Agreement under which~~ the ~~requisite~~accompanying ~~holders~~exhibit ofshall ~~the~~not ~~Debentures~~be ~~also~~incorporated ~~waived~~by ~~certain~~reference ~~defaults~~into ~~and agreed~~any tofiling ~~forbear~~with ~~from asserting certain remedies under~~ the ~~Debentures~~U.S. Securities and ~~related~~Exchange Commission ~~agreements~~made ~~through~~by ~~June 30~~the Company, ~~2013.~~whether ~~The~~made ~~2012~~before ~~Debentures~~or ~~and~~after the ~~2011~~date ~~Debentures~~hereof, ~~mature~~regardless ~~and~~of ~~become~~any ~~payable~~general incorporation language in ~~June,~~such ~~2013~~filings.

The closing of the second tranche consisted of the sale of an additional $1,042,000 principal amount of the 2012 Debentures. Two hundred thousand dollars ($200,000) principal amount of the 2012 Debentures was issued in consideration of the cancellation of the principal amount of indebtedness under two Demand Promissory Notes, each dated March 20, 2012 in the original principal amount of $100,000, issued in favor of Michael N. Taglich and Robert Taglich, respectively. As previously disclosed, the Demand Promissory Notes were issued on March 20, 2012 in connection with bridge loans made by Robert Taglich and Michael Taglich to provide the Company with temporary operating capital.

The Debentures, together with accrued and unpaid interest thereon, are convertible at the option of the holders into shares of the Company’s common stock (“Common Stock”) at a conversion price equal to $0.05 per share of Common Stock. Beginning after the date that is six months from the issuance of the applicable Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of Common Stock.

The Debentures bear interest at a rate of 8% per annum, compounded quarterly. The Debentures are secured by all the Company’s assets pursuant to the Security Agreement dated June 16, 2011 among the holders of the 2011 Debentures, the Company and CSC Trust Company of Delaware as collateral agent (the “Security Agreement”). The purchasers of the 2012 Debentures were made a party to the Security Agreement pursuant to a Joinder Agreement executed in connection with the issuance of the 2012 Debentures, a copy of which is included as Exhibit 10.3 to this Current Report on Form 8-K. The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion.

Taglich Brothers, Inc. (“Taglich Brothers”) acted as placement agent in connection with the offering. The Company paid Taglich Brothers a success fee equal to 7% of the gross proceeds of the sale of the 2012 Debentures. Taglich Brothers also received a warrant to purchase 1,350,000 shares of Common Stock, which is equal to 5% of the total number of shares into which the principal amount of the 2012 Debentures sold in the offering are convertible. The exercise price of the warrant is $0.0625 per share.

This summary of the material terms of the Debentures and related agreements is qualified in its entirety by reference to the full text of the Securities Purchase Agreement, Consent, Waiver and Forbearance Agreement, Joinder to Security Agreement, form of 2012 Debenture and Placement Agent Warrant, copies of which are included as Exhibits 10.1, 10.2, 10.3, 10.4 and 10.5, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Please refer to Item 1.01 of this Current Report.

Item 3.02. Unregistered Sales of Equity Securities.

Please refer to Item 1.01 of this Current Report.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

ExhibitNo.		Description
Exhibit No.		Description
10.1		Securities Purchase Agreement, dated May 4, 2012, among the Company and the purchasers signatory thereto.
99.1		SCOLR Pharma, Inc. press release, dated June 20, 2012.
10.2		Consent, Waiver and Forbearance Agreement, dated May 4, 2012, among the Company and the requisite holders of the Debentures signatory thereto.
10.3		Joinder to Security Agreement, dated May 4, 2012, among the Company, CSC Trust Company of Delaware, as collateral agent, and the holders of the 2012 Debentures signatory thereto.
10.4		Form of Debenture.
10.5		Placement Agent Warrant, issued June 11, 2012 in favor of Taglich Brothers, Inc.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCOLR Pharma, Inc.	~~SCOLR Pharma, Inc.~~
	(Registrant)	~~(Registrant)~~
June 15, 2012		By:	/s/ STEPHEN J. TURNER
June 28, 2012	By:	/s/ STEPHEN J. TURNER
(Date)		Stephen J. Turner	~~Stephen J. Turner~~
		President and Chief Executive Officer	~~President and Chief Executive Officer~~

Filing Compare · SCOLR Pharma, Inc.